SLS - SELLAS Life Sciences Group, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

SELLAS Life Sciences Group, Inc.

15 West 38th Street
10th Floor
New York, NY 10018
United States
917-438-4353
http://www.sellaslifesciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Dr. Angelos M. Stergiou M.D., ScD h.c.Founder, Pres, CEO & Director962.5kN/A1976
Mr. John Thomas Burns CPA, CPAVP of Fin. & Corp. Controller & Interim Principal Accounting Officer338.45kN/A1985
Ms. Barbara A. WoodExec. VP, Gen. Counsel & Sec.525.49kN/A1963
Mr. Martin G. BaumChief Operating OfficerN/AN/A1966
Dr. Dragan CicicSr. VP of Clinical Devel.N/AN/A1963
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Corporate Governance

SELLAS Life Sciences Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.